Logo image of OCX

ONCOCYTE CORP (OCX) Stock Price, Quote, News and Overview

NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD

2.65  -0.07 (-2.57%)

OCX Quote, Performance and Key Statistics

ONCOCYTE CORP

NASDAQ:OCX (2/21/2025, 8:00:01 PM)

2.65

-0.07 (-2.57%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.48
52 Week Low1.92
Market Cap55.81M
Shares21.06M
Float17.51M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)04-10 2025-04-10/amc
IPO12-30 2015-12-30


OCX short term performance overview.The bars show the price performance of OCX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

OCX long term performance overview.The bars show the price performance of OCX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of OCX is 2.65 USD. In the past month the price increased by 31.84%. In the past year, price decreased by -13.54%.

ONCOCYTE CORP / OCX Daily stock chart

OCX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About OCX

Company Profile

OCX logo image OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 43 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.

Company Info

ONCOCYTE CORP

15 Cushing

Irvine CALIFORNIA 92618 US

CEO: Ronald Andrews

Employees: 43

Company Website: https://oncocyte.com/

Investor Relations: https://investors.oncocyte.com/

Phone: 19494097600

ONCOCYTE CORP / OCX FAQ

What is the stock price of ONCOCYTE CORP today?

The current stock price of OCX is 2.65 USD. The price decreased by -2.57% in the last trading session.


What is the ticker symbol for ONCOCYTE CORP stock?

The exchange symbol of ONCOCYTE CORP is OCX and it is listed on the Nasdaq exchange.


On which exchange is OCX stock listed?

OCX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ONCOCYTE CORP stock?

7 analysts have analysed OCX and the average price target is 4.21 USD. This implies a price increase of 58.77% is expected in the next year compared to the current price of 2.65. Check the ONCOCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ONCOCYTE CORP worth?

ONCOCYTE CORP (OCX) has a market capitalization of 55.81M USD. This makes OCX a Micro Cap stock.


How many employees does ONCOCYTE CORP have?

ONCOCYTE CORP (OCX) currently has 43 employees.


What are the support and resistance levels for ONCOCYTE CORP (OCX) stock?

ONCOCYTE CORP (OCX) has a resistance level at 2.77. Check the full technical report for a detailed analysis of OCX support and resistance levels.


Is ONCOCYTE CORP (OCX) expected to grow?

The Revenue of ONCOCYTE CORP (OCX) is expected to decline by -66.95% in the next year. Check the estimates tab for more information on the OCX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ONCOCYTE CORP (OCX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ONCOCYTE CORP (OCX) stock pay dividends?

OCX does not pay a dividend.


When does ONCOCYTE CORP (OCX) report earnings?

ONCOCYTE CORP (OCX) will report earnings on 2025-04-10, after the market close.


What is the Price/Earnings (PE) ratio of ONCOCYTE CORP (OCX)?

ONCOCYTE CORP (OCX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.59).


What is the Short Interest ratio of ONCOCYTE CORP (OCX) stock?

The outstanding short interest for ONCOCYTE CORP (OCX) is 1.97% of its float. Check the ownership tab for more information on the OCX short interest.


OCX Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to OCX. When comparing the yearly performance of all stocks, OCX is a bad performer in the overall market: 74.93% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OCX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to OCX. Both the profitability and financial health of OCX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OCX Financial Highlights

Over the last trailing twelve months OCX reported a non-GAAP Earnings per Share(EPS) of -4.59. The EPS increased by 51.58% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.11%
ROE -449.08%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-20.99%
Sales Q2Q%-73.19%
EPS 1Y (TTM)51.58%
Revenue 1Y (TTM)-51.44%

OCX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to OCX. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 20.01% and a revenue growth -66.95% for OCX


Ownership
Inst Owners66.6%
Ins Owners1.25%
Short Float %1.97%
Short Ratio3.84
Analysts
Analysts74.29
Price Target4.21 (58.87%)
EPS Next Y20.01%
Revenue Next Year-66.95%